author-photo

Johannes Noe

Hoffmann-La Roche

19

Papers

2718

Citations

Citation Trend

Filter By

Papers (19) Sort By

JournalConferenceOthers

Alpha-T: An innovative decentralized (home-based) phase 2 trial of alectinib in ALK-positive (ALK+) solid tumors in a histology-agnostic setting.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Outcomes According to ALK Status Determined by Central IHC or FISH in Patients with ALK-Positive NSCLC Enrolled in the Phase III ALEX Study

2020 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (5)
TEMPORARY REMOVAL: Updated overall survival and final progression-free survival data for patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the ALEX study.

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (75)
ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-positive NSCLC: Pooled Analysis of Two Prospective Trials

2019 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (20)
Circulating free DNA as a prognostic biomarker in patients with advanced ALK+ NSCLC treated with alectinib from the global phase III ALEX trial.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-positive Advanced Non-small-cell Lung Cancer in the Global Phase III ALEX Study

2019 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (156)
79PClinical and analytical validation of an FDA approved comprehensive genomic profiling (CGP) assay incorporating multiple companion diagnostics for targeted and immunotherapies

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
1379PDImpact of the EML4-ALK variant on the efficacy of alectinib (ALC) in untreated ALK+ advanced NSCLC (aNSCLC) in the global phase III ALEX study

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (3)
JCES 01.27 Patients with ALK IHC-Positive/FISH-Negative NSCLC Benefit from ALK TKI Treatment: Response Data from the Global ALEX Trial

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (18)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号